|Day's Range||51.27 - 57.10|
|52 Week Range||37.05 - 75.36|
|PE Ratio (TTM)||-40.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26.
These stocks dropped despite a mostly flat market. Find out why.